🩹 Measles Post-Exposure Prophylaxis Timing Simulator

Exposure Identification and Immunity Status Verification

The very first — and most time-critical — step of measles post-exposure prophylaxis (PEP) is finding everyone who was exposed to a confirmed case while it was infectious, and quickly sorting them by immunity status. Measles is contagious from about 4 days before rash onset through 4 days after, and the virus lingers as an aerosol in a room for up to 2 hours after an infected person leaves. Every hour spent tracing contacts is an hour subtracted from the narrow PEP windows that follow.

• −4 to +4 d: Infectious period (relative to rash onset)
• ≤2 hours: Airborne persistence (in a vacated room)
• ~90%: Attack rate, susceptible (household contact exposure)
• Before 1957: Presumptive immunity cutoff (US convention; varies by country)

Defining "exposed" — who needs to be traced

Public health teams reconstruct the index case's movements during the infectious window and identify anyone who shared airspace with them, including:

• Household and close contacts (highest-risk, highest attack rate) • Anyone in the same room, waiting area, or enclosed space during the infectious period • Anyone entering that same room within 2 hours after the case departed, because measles virus remains suspended and infectious in air for that long • Healthcare workers and other patients in a clinic or ED where the case was evaluated • Airline passengers seated nearby (or the whole cabin section for extended flights)

The list is typically built from interviews, appointment logs, school/daycare attendance records, and increasingly from exposure-notification tools that cross-reference facility check-in times.

Checking each contact's immunity status

Once a contact list exists, each person is triaged against evidence of presumed immunity, most commonly:

• Documented receipt of 2 doses of MMR (or MMRV) vaccine, ≥28 days apart • Laboratory evidence of immunity (positive IgG) or prior lab-confirmed measles infection • Birth before the locally-defined presumptive-immunity cutoff year (e.g., 1957 in the US), reflecting near-universal natural exposure before vaccination programs existed • Healthcare personnel generally need documented evidence regardless of birth year, given occupational risk

Anyone who cannot show one of these is classified as susceptible and is immediately evaluated for PEP eligibility — vaccine vs. immunoglobulin — based on age, pregnancy status, and immune status.

Contact tracing and immunity verification must happen within hours, not days: the MMR vaccine PEP window closes at 72 hours post-exposure, and delays at the tracing stage are the single most common reason a susceptible contact misses the vaccine window entirely.

The 72-Hour MMR Vaccine Window

For susceptible contacts aged 12 months and older with no contraindication to a live vaccine, MMR given within 72 hours of exposure is the preferred post-exposure prophylaxis. Because MMR is a live attenuated vaccine, it works by racing the wild-type virus to establish an immune response — a race that is generally winnable only within the first three days after exposure.

• ≤72 hours: PEP window (from time of exposure)
• 12 months: Minimum eligible age (younger infants need IG instead)
• Yes: Prevents/modifies disease (if given within window)
• Yes: Confers lasting immunity (unlike IG, which is temporary)

Why 72 hours, and how the vaccine works in a race against wild virus

MMR contains a live, attenuated measles strain. After injection, it needs time to replicate locally and trigger an innate and adaptive immune response before the wild-type virus (acquired from the exposure) can establish itself and reach the incubation threshold for symptomatic disease.

Given within 72 hours, the attenuated vaccine strain has enough of a head start that the immune system can often neutralize the wild virus before it causes illness, or at minimum blunt the severity and shorten the course of disease. Beyond 72 hours, the wild virus has typically gained too much of a lead for the vaccine response to catch up reliably — though vaccination is still recommended afterward for future protection, it is no longer counted as effective PEP for this specific exposure.

Who is — and is not — eligible for vaccine PEP

MMR vaccine PEP is appropriate for susceptible contacts who are:

• At least 12 months old (or as young as 6 months in outbreak settings, per local guidance, though this dose does not count toward the routine 2-dose series) • Not pregnant • Not significantly immunocompromised (e.g., not on high-dose steroids, chemotherapy, or with certain immunodeficiencies) • Without a prior severe allergic reaction to a vaccine component

Contacts who fail any of these criteria are not vaccine-eligible and must be evaluated for immunoglobulin PEP instead, which works through a completely different, passive mechanism and has a longer — but still limited — window.

The 6-Day Immunoglobulin Window for Vaccine-Ineligible Contacts

When a susceptible contact cannot safely receive live MMR vaccine — infants under 6–12 months, pregnant individuals, or people who are significantly immunocompromised — human immunoglobulin (IG) offers a second-line PEP option. Because IG supplies pre-formed antibodies rather than training the immune system to make its own, it can be effective for a longer window: up to 6 days after exposure.

• ≤6 days: PEP window (144 hours from exposure)
• Passive antibody: Mechanism (pre-formed IgG, not immune training)
• Infants, pregnant, immunocompromised: Typical candidates (vaccine-ineligible groups)
• Weeks, not lasting: Protection duration (unlike vaccine-induced immunity)

Why immunoglobulin buys extra time — and why it is not a substitute for vaccination

IG (intramuscular or intravenous formulations) delivers concentrated, pre-formed antibodies against measles directly into circulation. Because it does not depend on the recipient mounting their own primary immune response, it can still blunt or prevent disease later in the incubation period than a vaccine could — hence the longer 6-day window.

However, this protection is passive and temporary: the borrowed antibodies gradually clear from circulation over weeks, and no long-lasting memory response is created. Once a contact is outside the window for live vaccine (or if IG itself was needed instead), they remain susceptible to future exposures until they can safely receive MMR vaccine at a later, medically appropriate time — often several months after IG, since residual antibodies can blunt the vaccine's own effectiveness if given too soon.

Dosing route and timing considerations

IG is generally more effective the earlier it is given within the 6-day window — administration soon after exposure is preferred over waiting until day 5 or 6. Two formulations are typically used:

• Intramuscular immunoglobulin (IGIM): standard option for most eligible contacts • Intravenous immunoglobulin (IGIV): often preferred for immunocompromised patients already receiving IVIG for other reasons, or when a higher, more reliable antibody dose is needed

After IG administration, the contact still requires ongoing symptom monitoring through the incubation period, since IG reduces but does not eliminate the risk of breakthrough disease.

A susceptible, vaccine-eligible contact who has already passed the 72-hour MMR window but is still within 6 days of exposure can — and generally should — still receive immunoglobulin, since passive protection is better than no PEP at all even for people who could otherwise have had the vaccine.

Post-Window Monitoring and Isolation Precautions

If a susceptible contact is identified too late for either PEP option — or PEP is declined — the strategy shifts from prevention to early detection and containment. Contacts are monitored daily through the full incubation period, and isolation precautions are triggered the moment any early symptom appears, so that if disease does develop, further transmission is minimized.

• 7–21 days: Incubation period (exposure to rash onset)
• ~10–12 days: Typical time to rash (from exposure)
• 2–4 days: Prodrome before rash (fever, cough, coryza, conjunctivitis)
• Day 4 post-rash: Isolate through (after rash onset, minimum)

What daily monitoring looks like

Public health or occupational health staff check in with the susceptible contact daily (by phone, app, or in person) throughout the incubation window, watching for the classic measles prodrome:

• Fever, often high and rising over several days • Cough, coryza (runny nose), and conjunctivitis (the "three C's") • Koplik spots (small white spots on the buccal mucosa), a near-pathognomonic early sign • The maculopapular rash itself, which typically begins on the face/hairline and spreads downward

Contacts are usually instructed to stay away from settings with vulnerable people (hospitals, schools, congregate care) during the monitoring period, and to call ahead — rather than simply walk in — if symptoms develop, so that the receiving facility can prepare airborne-isolation precautions.

Isolation precautions if symptoms appear

If a monitored contact develops symptoms consistent with measles, they are placed into isolation immediately:

• Airborne precautions: negative-pressure room if inpatient, or strict home isolation if managed in the community • Isolation continues from 4 days before through 4 days after rash onset, matching the known infectious period • Any new contacts made by this now-symptomatic individual must themselves be traced and evaluated for PEP, potentially restarting the whole cycle • Confirmatory testing (RT-PCR, IgM serology) is obtained to verify the diagnosis and support public health reporting

This monitor-and-isolate pathway is deliberately the fallback, not the goal — it accepts a real chance of secondary transmission that PEP, given in time, was designed to prevent.

Why PEP Speed Is the Crux of Measles Outbreak Control

Measles is among the most contagious pathogens known to humans, with a basic reproduction number (R0) estimated between 12 and 18 in fully susceptible populations — meaning a single case can seed a dozen or more secondary infections. Interrupting these transmission chains depends almost entirely on how quickly contacts are identified and offered PEP, because both the vaccine and immunoglobulin windows are measured in hours to days, not weeks.

• 12–18: R0 (basic reproduction number) (among the highest of any pathogen)
• ~95%: Herd immunity threshold (2-dose MMR coverage needed)
• Very low: Airborne infectious dose (aerosol transmission, no direct contact needed)
• Hours matter: PEP effectiveness decay (72h vaccine / 6d IG windows)

The transmission-chain-interruption model

Every measles case that goes unrecognized, or whose contacts are traced too slowly, has the potential to generate 12–18 further cases if the surrounding population is not well-immunized. Each of those secondary cases can, in turn, seed its own cluster. Outbreak control works by cutting as many of these branches as early as possible:

• Speed of case identification and reporting to public health • Speed and completeness of contact tracing • Speed of immunity-status verification • Speed of PEP delivery — vaccine within 72 hours where eligible, IG within 6 days otherwise

Because both PEP windows are short and non-negotiable, a delay at any single step in this chain can convert a preventable exposure into an active case, which then restarts the whole tracing-and-PEP cycle for a new, larger set of contacts.

Population-level implications

Individual PEP decisions aggregate into population-level outbreak trajectories. Communities with high 2-dose MMR coverage (~95%, the herd immunity threshold for a pathogen this contagious) rarely sustain outbreaks even when an index case is imported, because most contacts are already immune and PEP is only needed for a small residual group.

In under-vaccinated communities, however, a single importation can encounter a large pool of susceptible contacts, and outbreak size becomes extremely sensitive to how fast the PEP machinery — tracing, eligibility screening, vaccine or IG administration — can operate. This is why measles is often described as a "canary in the coal mine" for gaps in vaccination coverage and public health response capacity: it exploits any slowdown in contact tracing and PEP delivery faster than almost any other vaccine-preventable disease.

Historically, outbreaks are brought under control fastest when PEP teams achieve vaccine-eligible contact vaccination within 24–48 hours of exposure identification — well inside the 72-hour window — leaving margin for the inevitable delays in locating and reaching every contact on the list.